Payment overview · 2025
General Payments
$564.54
36 reported records · 15 companies
Healthcare provider profile · identity verified
Richard E. Mohr, MD
Allopathic & Osteopathic Physicians|Family Medicine · FLORENCE, SC · NPI 1396939393
Verified facts
What the public records show
CMS Open Payments records show Richard E. Mohr, MD received $564.54 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.16 | 25.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.44 | 18.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.61 | 10.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.16 | 8.2% | 2 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $35.09 | 6.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.07 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.61 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.69 | 3.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.33 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.89 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.78 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.43 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.54 | 2.6% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $13.72 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.02 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $532.27 | 35 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.86 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.88 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.37 | 5 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.56 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.41 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 108 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 102 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 402 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 377 | 80 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 372 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 76 |
| Prednisone | Prednisone | 300 | 147 |
| Gabapentin | Gabapentin | 297 | 61 |
| Losartan Potassium | Losartan Potassium | 291 | 61 |
| Lisinopril | Lisinopril | 289 | 67 |
| Omeprazole | Omeprazole | 276 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 52 |
| Alprazolam | Alprazolam | 257 | 44 |
| Furosemide | Furosemide | 236 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 54 |
| Trazodone Hcl | Trazodone Hcl | 192 | 40 |
| Potassium Chloride | Potassium Chloride | 184 | 41 |
| Metformin Hcl | Metformin Hcl | 178 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 41 |
| Metformin Hcl Er | Metformin Hcl | 169 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 39 |
| Azithromycin | Azithromycin | 164 | 118 |
| Carvedilol | Carvedilol | 153 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 30 |
| Clonazepam | Clonazepam | 149 | 19 |
| Ozempic | Semaglutide | 149 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 31 |
| Lorazepam | Lorazepam | 145 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 33 |
| Meloxicam | Meloxicam | 137 | 30 |
| Montelukast Sodium | Montelukast Sodium | 137 | 40 |
| Allopurinol | Allopurinol | 128 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 23 |
| Eliquis | Apixaban | 108 | 19 |
| Tramadol Hcl | Tramadol Hcl | 106 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 28 |
| Mounjaro | Tirzepatide | 102 | 19 |
| Diazepam | Diazepam | 98 | 16 |
| Bupropion Xl | Bupropion Hcl | 96 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 21 |
| Pregabalin | Pregabalin | 93 | 16 |
| Finasteride | Finasteride | 91 | 15 |
| Sertraline Hcl | Sertraline Hcl | 88 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 15 |
| Baclofen | Baclofen | 86 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 15 |
| Ibuprofen | Ibuprofen | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | 13 |
| Promethazine Hcl | Promethazine Hcl | 70 | 14 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 68 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 26 |
| Meclizine Hcl | Meclizine Hcl | 67 | 24 |
| Donepezil Hcl | Donepezil Hcl | 66 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 17 |
| Levofloxacin | Levofloxacin | 60 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 16 |
| Celecoxib | Celecoxib | 59 | 16 |
| Clonidine Hcl | Clonidine Hcl | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 11 |
| Spironolactone | Spironolactone | 57 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 55 | suppressed |
| Sucralfate | Sucralfate | 54 | 27 |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Enalapril Maleate | Enalapril Maleate | 52 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | suppressed |
| Fluconazole | Fluconazole | 50 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 13 |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 33 |
| Simvastatin | Simvastatin | 45 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 28 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Famotidine | Famotidine | 36 | 11 |
| Fentanyl | Fentanyl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 29 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 17 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Movantik | Naloxegol Oxalate | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 11 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Vardenafil Hcl | Vardenafil Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $564.54 · 36 records | ABBVIE INC. | AIRSUPRA, Auvelity, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, JATENZO, MOUNJARO, NALOCET, NURTEC ODT, OTEZLA, Ozempic, PROLATE, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, TANLOR, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error